Costol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Costol

Quick Facts about Costol

Property Description
Active Ingredient Mefenamic Acid (INN)
Form Oral Solid (Tablet or Capsule)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Pain Relief, Inflammation Reduction, and Fever Reduction
Origin Synthetic Compound

What Type of Medicine is Costol and Its Main Component?

Costol is a synthetic, single-ingredient medicinal product classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its core therapeutic substance is Mefenamic Acid (INN), a compound chemically categorized as a fenamate derivative. This chemical structure is clinically recognized to offer a faster onset of action compared to some other NSAIDs, making it a preferred choice for acute, short-term relief.

This classification places Costol in a major pharmacological group distinct from antibiotics or opioids. The drug is designed for systemic action following its intake. Mefenamic Acid's defining characteristic is its role as an anti-inflammatory, analgesic, and antipyretic agent. This means the medicine is recognized to help ease discomfort by interrupting the body's processes that cause pain and swelling, such as managing painful symptoms often associated with dental procedures or muscular strain.

Physical Form, Administration, and General Purpose

Costol is typically manufactured as an oral solid form, such as a tablet or capsule, and is intended for oral administration. This physical design ensures efficient systemic delivery of the active ingredient.

The primary general purpose of Costol is rooted in its established mechanism as a Cyclooxygenase (COX) inhibitor. By interfering with the synthesis of prostaglandins—the chemical messengers responsible for signaling pain and initiating inflammation—the medication delivers relief. The drug's mechanism effectively addresses symptoms of pain and inflammation associated with various acute conditions. This action provides general pain relief, helps to decrease inflammation (swelling and tenderness), and assists the body in lowering fever. The composition of the product features Mefenamic Acid, along with necessary inactive ingredients, known as excipients, required for proper drug absorption.

Regulatory References

  1. Mefenamic Acid - LiverTox - NCBI Bookshelf (NIH)

What side effects are possible with Costol?

Possible Side Effects and Safety Information

The safety profile of Costol (Mefenamic Acid) is officially categorized by potential adverse reactions across several physiological systems. Common effects, reported in 1% to 10% of users, primarily involve the Gastrointestinal Disorders system and include diarrhea, stomach pain, nausea, and vomiting. Other frequently listed effects fall under Nervous System Disorders, such as headache and dizziness.


Serious Adverse Reactions

Official regulatory documents emphasize the risk of rare but serious events. The drug belongs to a class associated with an increased risk of serious Cardiovascular Thrombotic Events, including myocardial infarction (heart attack) and stroke. Serious Gastrointestinal Events, such as bleeding, ulceration, and perforation, are documented risks that can occur at any time during treatment. Rare but severe Cutaneous Adverse Reactions (e.g., Stevens-Johnson Syndrome) are also noted, often with the highest risk of onset early in the course of therapy.


Population-Specific Safety Considerations

Certain official restrictions apply to specific populations. The medicine is contraindicated in patients with severe hepatic, renal, or cardiac failure. Older adults are recognized as having an increased risk of serious, potentially fatal, gastrointestinal adverse reactions. The use of Costol is officially restricted for pregnant women from approximately 20 weeks gestation onward due to documented risks of fetal harm. Furthermore, the drug is contraindicated in patients with a history of allergic reactions to aspirin or other NSAIDs and for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the Costol (Mefenamic Acid) overdose profile by its documented manifestations and the required emergency response. Overdose may present with serious effects on the Central Nervous System (CNS) and the Gastrointestinal (GI) system. Officially documented manifestations include seizures (convulsions), coma, altered mental status, lethargy, vertigo, and muscle twitching. GI effects may include nausea, vomiting, epigastric pain, and serious gastrointestinal bleeding, ulceration, or perforation.

Overdose has the potential for life-threatening outcomes such as acute renal failure and respiratory depression.

Official Emergency Actions

Emergency medical care is required for any suspected overdose. Immediate medical assistance is mandated when an individual experiences severe symptoms, including seizures, trouble breathing, or loss of consciousness. You must contact emergency services immediately under these conditions.

Management is strictly symptomatic and supportive care, as no specific antidote is known for Mefenamic Acid overdose. Officially described supportive procedures include gastric lavage and the administration of activated charcoal. Hospital monitoring is required, and patients should be observed for at least 12 hours.

Therapeutic Uses of Costol

What Costol Treats: Main Uses and Benefits

Costol (Mefenamic Acid) is commonly used to help manage symptoms related to physical discomfort across acute, pain-driven, and inflammatory contexts. The medication may support patients during episodes of heightened discomfort and symptoms that create noticeable physiological strain.

It is applied in situations involving certain distressing symptoms of pain, inflammation, and fever. The indications for which it is commonly used include primary dysmenorrhea (menstrual pain/cramps), muscular strains, minor traumatic pain, discomfort following dental or minor surgical procedures, and symptomatic arthritis flares.

The primary therapeutic benefit is to offer symptomatic relief that helps patients cope more steadily with symptom fluctuations.

“Costol is applied when symptoms cluster into patterns requiring short-term supportive management, contributing to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Acute Episodic Symptoms

Symptom Domain Typical Context Patient Benefit
Cyclical Pain/Cramping Menstruation (Primary Dysmenorrhea) May help ease the overall symptom burden.
Local Pain/Swelling Muscular Strain, Post-Dental Procedure May support the patient during episodes of heightened discomfort.
Systemic Fever Acute febrile illness (over 6 months) May assist with maintaining a sense of stability.

Regulatory References

  1. Mefenamic Acid MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Costol?

Costol (Mefenamic Acid) eligibility is strictly defined by regulatory authorities based on age, physiological status, and pre-existing medical conditions.


Populations Who Must Not Use Costol (Contraindicated)

Use is strictly prohibited in patients with the following conditions, as detailed in official regulatory labels:

  • Known Hypersensitivity to mefenamic acid, aspirin, or any other NSAIDs (Nonsteroidal Anti-inflammatory Drugs).
  • Active Gastrointestinal Disease, including active ulceration, chronic inflammation, or Inflammatory Bowel Disease (IBD).
  • Severe Organ Failure, specifically severe renal (kidney) failure, severe hepatic (liver) failure, or severe uncontrolled heart failure.
  • Pregnancy: Contraindicated during the last trimester (from 30 weeks gestation) and should be avoided from 20 weeks gestation.
  • Cardiovascular: For the treatment of peri-operative pain in the setting of CABG surgery.

Restricted and Conditional Use

Population Group Eligibility Status
Pediatric Patients Not established or not recommended for children under 14 years of age (tablets/capsules).
Older Adults (ge 65) Use must be conditional: lowest effective dose for the shortest duration due to higher risk of GI and renal events.
Lactating Women Not recommended due to potential for adverse reactions in the nursing infant.
Fertility Not recommended for women attempting to conceive due to potential impairment of female fertility.

What should I know about interactions with other medicines?

Official Interaction Profile for Costol (Mefenamic Acid)

The official interaction profile for Costol is defined by documented pharmacodynamic and pharmacokinetic interactions that may alter the exposure of co-administered drugs or increase the risk of specific adverse outcomes, based on regulatory labeling.

Interaction Category Documented Outcome/Constraint
Exposure Modification (PK) Reduces the renal clearance of Lithium and Methotrexate, formally elevating their plasma concentrations. Magnesium Hydroxide Antacids significantly increase the rate and extent of Mefenamic Acid absorption.
Risk Reinforcement (PD) Enhances the effects of Oral Anticoagulants (e.g., Warfarin) and Anti-platelet Agents, increasing the regulatory documented risk of bleeding.
Efficacy Reduction (PD) May reduce the effect of ACE Inhibitors, ARBs, and Diuretics, and can interfere with the activity of Mifepristone.
Administration Restrictions Co-administration with other NSAIDs (including Ketorolac) is not recommended due to increased adverse event risk. Must not be taken for 8 to 12 days after Mifepristone administration.

Interactions with antihypertensive agents and Alcohol carry regulatory warnings regarding risk elevation for renal impairment or gastrointestinal bleeding, respectively. This increased risk of renal impairment with certain blood pressure medications is specifically noted in regulatory documents as being heightened in elderly patients. This structure provides formal constraints on combination use based solely on government-verified data.

Mechanism of Action

Receptor-Mediated Signal Modulation

Costol interfaces with signaling processes by acting as a selective ligand at specific receptor- or enzyme-mediated signaling sites within the target biological system. This intervention modifies the early molecular steps that determine systemic physiological outcomes.


Targeted Pathway Adjustment

The compound is relevant in systems requiring precise pathway adjustment, particularly influencing systems where specific transmitters or mediators dominate the activity profile. Costol initiates or suppresses signaling sequences, modulating the response to excessive mediator activity, and contributing to the establishment of a revised activity level within the targeted pathways.


Physiological Response Influence

Through its action on core mechanistic cascades, Costol influences the downstream effectors of high-amplitude physiological responses. This process supports the establishment of a state driven by distinct signaling patterns and influences the resultant kinetic activity of the biological system.

Dosage and Administration Information

How Costol is Used: Official Administration Guidelines

Costol (Mefenamic Acid) is an oral medication whose usage follows established protocols defining dose, frequency, and duration. The primary principle is the use of the lowest effective dose for the shortest possible duration.

Usage Parameter Official Regulatory Guidance
Route of Administration Oral (swallowed)
Standard Dosing Schedule Initial dose of 500 mg, followed by a maintenance dose of 250 mg.
Frequency 250 mg taken every 6 hours as needed, or 500 mg three times daily in certain regimens.
Intake Condition Must be taken with food or milk or a full glass of water.
Maximum Duration Acute pain therapy not to exceed 7 days; menstrual pain therapy typically 2 to 3 days.
Specific Populations For older adults, the lowest effective dose should be used for the shortest duration.

Official Procedural Structure

The established protocol begins with the intake of the 500 mg loading dose at the start of the required treatment course. This is followed by the 250 mg maintenance dose taken at fixed time intervals (every 6 hours). If a scheduled dose is missed, standard instructions involve skipping that dose and continuing the regular schedule without taking a double dose. The overall use protocol is defined as short-term, ensuring the medicine is promptly discontinued when the limit (e.g., 7 days) is reached.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Costol (Mefenamic Acid)

The research evidence for Costol focuses primarily on what was studied in short-term, acute symptom management, largely documented through Randomized Controlled Trials (RCTs) and systematic reviews. The goal of this overview is to describe what type of research exists for the medicine and what aspects of its use have been studied.


Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

Research has been extensively conducted in the context of primary dysmenorrhea, which are conditions characterized by fluctuating or episodic manifestations of pain during menstruation. Studies monitored outcomes related to physical discomfort. Findings describe patterns observed in the studies related to measured changes in pain level scores and the recording of concurrent analgesic use over a few days. The evidence contributes to the broader evidence landscape by describing how symptoms were observed to change in the observed populations of young women and adolescents with regular cycles. Follow-up durations were limited, with most studies tracking response for only one to three cycles.


Evidence for Acute Mild to Moderate Pain

Studies for acute, short-term pain conditions—such as discomfort following dental procedures—primarily utilized single-dose RCTs and systematic reviews. Research explored short-term symptom changes and monitored outcomes related to episodic or acute changes. Findings describe patterns observed in the studies related to the speed at which pain measurements changed and the duration over which a measurable difference was observed. Sample sizes were modest in many of the individual acute pain trials, and long-term outcomes were not extensively characterized by the existing research.


Evidence for the Antipyretic Effect (Fever Reduction)

Comparative trials were used to evaluate the compound's profile related to measured changes in body temperature in both adults and pediatric patients generally over six months of age. These studies reported measurements concerning the degree of temperature reduction and the time it took for that measured reduction to occur. Data for certain groups remain insufficient, including children under six months or complex comorbidities, meaning long-term effects on chronic febrile conditions are not fully established.


What Research Gaps and Uncertainties Remain

A key observation across the research base is that the evidence is limited, with many trials having modest sample sizes and follow-up durations restricted to the acute phase of symptoms. Comparative evidence is lacking in some areas, particularly when comparing Costol against all available alternatives across diverse patient groups. The research primarily focuses on acute changes, meaning the use of the compound outside of acute, temporary changes in symptoms has not been extensively characterized. Research describes group patterns and does not provide predictions for individual responses.

Key Studies & References

  1. Mefenamic Acid - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

Frequently Asked Questions (FAQ)

Common questions about Costol (FAQ)


Q: How quickly can someone expect to feel the effects of Costol?

Official product information states that the concentration of the active ingredient in the bloodstream typically reaches its highest level within two to four hours after oral intake. The peak plasma level is the point in time when the highest concentration of the active ingredient has entered the systemic circulation.


Q: Can Costol be used by children, or is it only for adults?

The oral tablet and capsule forms of Costol are typically indicated for use in patients aged 14 years and older. For patients younger than 14, regulatory documents state that the use of this form is generally not recommended. This is due to limited data supporting safety and efficacy in this age group.


Q: Do official studies show that Costol is better than a placebo?

Studies reviewed by regulatory bodies for conditions such as primary dysmenorrhea examined the drug's effect compared to a non-drug control, or placebo. Evidence indicates that Costol was generally found to be superior to placebo in reducing pain measures within those clinical trials.


Q: Is it normal to feel a little tired when first starting Costol?

Unusual tiredness or weakness is noted in official adverse event reporting but is not typically listed as a common or mild effect. Official regulatory information notes that this symptom is sometimes associated with rare, serious adverse events, such as liver or kidney injury.


Q: How does the effectiveness of Costol change over time?

Costol is formally indicated only for short-term use, which usually does not exceed seven days for acute conditions. Due to this restriction, its effectiveness and safety for use over longer periods of time have not been extensively established or characterized in clinical research.


Q: Does the time of day I take Costol matter?

Regulatory information explicitly defines the need to maintain the prescribed 6-hour dosing interval and to take the medication with food or milk. These requirements for interval and food intake are the primary time-related factors described in the official instructions.


Q: If Costol has an interaction with another drug, what does that mean in simple terms?

A drug interaction means that when two medicines are taken together, one or both may be changed in a way that affects how they work. This can result in the active ingredient's level in the body being higher or lower than expected, or it may raise the risk of certain side effects. Regulatory documents list specific types of interactions that may occur.


Q: What is the difference between Costol and a supplement?

Regulatory authorities classify Costol as a Human Prescription Drug belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. This classification means it is subject to strict testing, approval, and safety monitoring rules that differ significantly from those applied to dietary supplements.


Q: Do I need a prescription from a doctor to get Costol?

Costol is formally classified as a prescription-only medication (Rx only) across major regulatory jurisdictions. This means it must be obtained with a valid prescription from a licensed healthcare provider.


Q: How long does Costol typically stay in a person's system?

The time it takes for half of the dose to be removed from the body is known as the elimination half-life, and this figure is approximately two to four hours. Regulatory data states this figure. The half-life is the time required for the concentration of the active ingredient in the body to be reduced by half.


Q: Are generic versions of Costol available, and are they the same?

The active ingredient of Costol is Mefenamic Acid, which is widely available as an approved generic drug. Generic alternatives are approved based on regulatory standards that establish bioequivalence to the brand-name product regarding dosage, strength, and quality.


Q: Can Costol affect the results of a standard blood test?

Official regulatory information notes that the medicine may affect the results of certain laboratory tests. For example, it may prolong prothrombin time or potentially cause a false-positive result for urinary bile using a specific diagnostic test.


Q: Is Costol known to be addictive or habit-forming?

Regulatory information classifies Costol as a Nonsteroidal Anti-inflammatory Drug (NSAID) and does not list it as a controlled substance with the Drug Enforcement Administration (DEA). NSAIDs, including Costol, are not known to be addictive or habit-forming.


Q: Can Costol be taken at the same time as a multivitamin?

Official product information states that patients should inform their healthcare provider of all supplements they are taking, including vitamins and herbs. While a specific interaction with standard multivitamins is not commonly listed, this disclosure is recommended due to the potential for general interaction risks.


Q: What should I do if I suspect a severe side effect from Costol?

Official regulatory information recommends the immediate discontinuation of the medicine and seeking emergency medical services if symptoms suggestive of a serious adverse event occur. These symptoms include signs of bleeding, stroke, or a severe allergic reaction.


Q: Does Costol typically cause weight gain or weight loss?

Unusual weight gain and unexplained weight loss are noted in official adverse event data but are not reported as common, typical side effects. These changes in weight are sometimes reported in association with serious conditions like fluid retention or liver injury.


Q: Is Costol considered a 'new' medicine, or has it been around for a while?

The active ingredient of Costol, Mefenamic Acid, was first introduced and approved in major markets in the 1960s. This means it is considered an established medicine that has been in use under regulatory oversight for several decades.


Q: Does Costol cause sensitivity to sunlight?

Increased sensitivity of the skin to sunlight, a condition known as photosensitivity, is noted in adverse event data. This is listed as a less common or rare side effect associated with the drug.


Q: Does Costol interact with any herbal supplements?

Official regulatory information recommends that patients inform their healthcare provider of any herbal supplements they are taking. This is suggested because combinations may carry a risk of increased side effects, such as a higher risk of bleeding, and some specific herbal interactions are documented.


How should Costol be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documentation requires Costol (Mefenamic Acid) to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container, which should remain tightly closed to protect it from moisture and light. It is strictly required that Costol be kept out of the reach and sight of children.

Storage Restriction Requirement
Temperature Do not store above 30 C (Do Not Freeze)
Protection Keep away from excess heat, moisture, and direct light

For disposal, unused or expired Costol should be taken to a drug take-back program or disposed of according to the official FDA household procedure. The product must not be released into the environment or poured down drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Costol found in:

A-Z Index: